Amended Current Report Filing (8-k/a)
26 Abril 2023 - 4:28PM
Edgar (US Regulatory)
0001413754
true
0001413754
2022-12-27
2022-12-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Amendment
No. 1 to
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 26, 2023 (December 27, 2022)
MARIZYME,
INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-53223 |
|
82-5464863 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
555
Heritage Drive, Suite 205, Jupiter, Florida |
|
33458 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(561)
935-9955
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Not
applicable. |
|
|
|
|
EXPLANATORY
NOTE
This
Amendment No. 1 to the Current Report on Form 8-K of Marizyme Inc. (the “Company”) filed with the Securities and Exchange
Commission on December 28, 2022 (the “Original Report”) is being filed to correct the report of voting results from the Company’s
Annual Meeting of Shareholders that took place on December 27, 2022. In the Original Report, the votes of certain holders of convertible
notes were counted because the convertible notes they are holding contain a provision (the “Voting Provision”) that entitles
them to vote with the common stockholders on an as converted to common stock basis with respect to all corporate matters of the Company
on which the holders of Common Stock are entitled to vote, without having converted their convertible notes into common stock. Although
the Nevada Revised Statutes allow for this Voting Provision, this allowance is conditioned on the Company’s articles of incorporation
containing the Voting Provision and the Company’s articles of incorporation, as currently amended and restated (the “Articles”),
do not contain that provision. The Company will endeavor to amend the Articles to include the Voting Provision going forward.
Item
5.07 Submission of Matters to a Vote of Security Holders
On
December 27, 2022, Marizyme, Inc. (the “Company”) held its Annual Meeting of Shareholders virtually via live audio webcast
at https://agm.issuerdirect.com/mrzm. A total of 20,964,240 shares of common stock representing 51.73% of the aggregate shares outstanding
and eligible to vote and constituting a quorum were represented in person or by valid proxies at the annual meeting.
David
Barthel, Terry Brostowin, Esq., Dr. William Hearl, Julie Kampf, Dr. Vithalbhai Dhaduk, Michael Stewart, and Dr. Nilesh Patel were each
elected as directors of the Company to serve until the next annual meeting of shareholders.
The
shareholders approved an amendment to the Company’s Articles of Incorporation, as amended to date, to increase the total number
of shares of the Company’s authorized common stock to 75,000,000, on a post-reverse stock split basis.
The
shareholders ratified an amendment to the Company’s Amended and Restated 2021 Stock Incentive Plan.
The
shareholders also ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal
year ending on December 31, 2022.
The
shareholders voted in favor of the non-binding advisory proposal that the preferred frequency of stockholder advisory votes on executive
compensation, referred to as “say-on-frequency,” be approved for every one year.
The
final voting results on these matters were as follows:
1.
Election of Directors:
Name | |
Votes For | | |
Votes Withheld | | |
Broker Non-Votes | |
David Barthel | |
| 19,637,511 | | |
| 1,301,442 | | |
| 25,287 | |
Terry Brostowin, Esq. | |
| 19,631,511 | | |
| 1,307,442 | | |
| 25,287 | |
Dr. William Hearl | |
| 19,332,511 | | |
| 1,606,442 | | |
| 25,287 | |
Julie Kampf | |
| 18,313,011 | | |
| 2,625,942 | | |
| 25,287 | |
Dr. Vithalbhai Dhaduk | |
| 18,313,011 | | |
| 2,625,942 | | |
| 25,287 | |
Michael Stewart | |
| 19,332,511 | | |
| 1,606,442 | | |
| 25,287 | |
Dr. Nilesh Patel | |
| 18,613,011 | | |
| 2,325,942 | | |
| 25,287 | |
2.
Approval of the Amendment to the Company’s Articles of Incorporation, as Amended to Date, to Increase the Total Number of Shares
of Authorized Common Stock to 75,000,000 on a Post-Reverse Stock Split Basis:
Votes For | | |
Votes Against | | |
Votes Abstained | | |
Broker Non-Votes | |
| 19,657,460 | | |
| 1,306,780 | | |
| N/A | | |
| N/A | |
3.
Ratification of the Amendment to the Company’s Amended and Restated 2021 Stock Incentive Plan:
Votes For | | |
Votes Against | | |
Votes Abstained | | |
Broker Non-Votes | |
| 19,655,942 | | |
| 1,308,298 | | |
| N/A | | |
| N/A | |
4.
Ratification of the Appointment of WithumSmith+Brown PC as Independent Registered Public Accounting Firm for the Fiscal Year Ending December
31, 2022:
Votes For | | |
Votes Against | | |
Votes Abstained | | |
Broker Non-Votes | |
| 20,964,233 | | |
| 1 | | |
| 6 | | |
| N/A | |
5.
Non-Binding Advisory Vote on Preferred Frequency of Stockholder Advisory Votes on Executive Compensation, referred to as “Say-On-Frequency”:
One Year | | |
Two Years | | |
Three Years | | |
Votes Abstained | | |
Broker Non-Votes | |
| 12,633,459 | | |
| 7,619,934 | | |
| 680,559 | | |
| 5,001 | | |
| 25,287 | |
In
light of the results of the “say-on-frequency” vote and other factors, the Board of Directors has determined that the Company
will hold future advisory votes on the compensation of its named executive officers on an annual basis until the next “say-on-frequency”
vote is conducted or until the Board of Directors determines that it is in the best interest of the Company to hold such votes with a
different frequency. The next advisory vote regarding the frequency of say on frequency votes is required to occur no later than the
Company’s 2028 Annual Meeting of Shareholders.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, Marizyme, Inc. has duly caused this current report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
April 26, 2023 |
MARIZYME,
INC. |
|
|
|
|
By: |
/s/
David Barthel |
|
|
David
Barthel |
|
|
Chief
Executive Officer |
Marizyme (QB) (USOTC:MRZM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Marizyme (QB) (USOTC:MRZM)
Gráfica de Acción Histórica
De May 2023 a May 2024